U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Pramlintide is an analog of human amylin. Amylin is co-secreted with insulin from pancreatic beta cells and acts centrally to slow gastric emptying, suppress postprandial glucagon secretion, and decrease food intake. These actions complement those of insulin to regulate blood glucose concentrations. Amylin is relatively deficient in patients with type 2 diabetes, depending on the severity of beta-cell secretory failure, and is essentially absent in patients with type 1 diabetes. Through mechanisms similar to those of amylin, pramlintide improves overall glycemic control, reduces postprandial glucose levels, and reduces bodyweight in patients with diabetes using mealtime insulin. SYMLIN® (pramlintide acetate) is indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy.

Approval Year

2005
131
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
SYMLIN

Approved Use

SYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.

Launch Date

2005

Sample Use Guides

In Vivo Use Guide
•Upon initiation of SYMLIN® (pramlintide acetate), reduce mealtime insulin dose by 50%. Monitor glucoses frequently and individualize subsequent insulin dose adjustments. •Type 1 Diabetes: Start at 15 mcg subcutaneously before major meals. Increase in 15 mcg increments to a maximum premeal dose of 30 or 60 mcg; if not tolerated, reduce to 30 mcg, as tolerated. •Type 2 Diabetes: Start at 60 mcg subcutaneously before major meals then increase to 120 mcg before meals, as tolerated. •Wait at least 3 days between dose titrations to minimize nausea.
Route of Administration: Other
Name Type Language
PRAMLINTIDE
INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
TRIPRO-AMYLIN
Common Name English
LYS-CYS-ASN-THR-ALA-THR-CYS-ALA-THR-GLN-ARG-LEU-ALA-ASN-PHE-LEU-VAL-HIS-SER-SER-ASN-ASN-PHE-GLY-PRO-ILE-LEU-PRO-PRO-THR-ASN-VAL-GLY-SER-ASN-THR-TYR-NH2
Common Name English
AC137
Code English
pramlintide [INN]
Common Name English
PRAMLINTIDE [USAN]
Common Name English
PRAMLINTIDE [MI]
Common Name English
AC-137
Code English
AC-0137
Code English
PRAMLINTIDE [MART.]
Common Name English
AC0137
Code English
PRAMLINTIDE [VANDF]
Common Name English
Pramlintide [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29711
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
WHO-VATC QA10BX05
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
NDF-RT N0000177910
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
WHO-ATC A10BX05
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
LIVERTOX NBK548949
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
NDF-RT N0000020064
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
Code System Code Type Description
DRUG CENTRAL
2236
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
NCI_THESAURUS
C61901
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
DRUG BANK
DB01278
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
PUBCHEM
70691388
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
MESH
C105254
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
WIKIPEDIA
PRAMLINTIDE
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
MERCK INDEX
m9098
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY Merck Index
CAS
151126-32-8
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
INN
7448
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
EVMPD
SUB09993MIG
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
USAN
GG-79
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
FDA UNII
D3FM8FA78T
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
DAILYMED
D3FM8FA78T
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
ChEMBL
CHEMBL2103758
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
LACTMED
Pramlintide
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
IUPHAR
7482
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
RXCUI
139953
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID801027623
Created by admin on Sat Dec 16 00:24:23 GMT 2023 , Edited by admin on Sat Dec 16 00:24:23 GMT 2023
PRIMARY
ACTIVE MOIETY
PRAMLINTIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966